# Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

> **NCT01546142** · PHASE3 · COMPLETED · sponsor: **Kythera Biopharmaceuticals** · enrollment: 516 (actual)

## Conditions studied

- Moderate or Severe Submental Fullness

## Interventions

- **DRUG:** Deoxycholic acid injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01546142
- **Lead sponsor:** Kythera Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-05
- **Final completion:** 2013-08
- **Target enrollment:** 516 (ACTUAL)
- **Last updated:** 2015-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01546142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01546142, "Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01546142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*